SCHEMBL13612259

SCHEMBL13612259

CNC(=S)N/N=C/C1CCCCN1Cc1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
LMNA P02545 4/20 0.37
ALOX12 P18054 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
HTT P42858 2/20 0.36
POLB P06746 2/20 0.36
HPGD P15428 2/20 0.36
GAA P10253 1/20 0.36
THRB P10828 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MAPT P10636 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
CCR2 P41597 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4338699 1.00 ALDH1A1 (0.39) ALDH1A1CNR1CNR2LMNAALOX12
SCHEMBL4326605 0.86 ALDH1A1 (0.38) ALDH1A1CNR1CNR2LMNAALOX12
SCHEMBL4326601 0.86 ALDH1A1 (0.38) ALDH1A1CNR1CNR2LMNAALOX12
SCHEMBL4325060 0.86 SMN1; SMN2 (0.43) LMNAALOX12SMN1; SMN2GAANPC1
SCHEMBL13612399 0.86 SMN1; SMN2 (0.43) LMNAALOX12SMN1; SMN2GAANPC1
SCHEMBL4331355 0.83 GAA (0.44) ALDH1A1LMNASMN1; SMN2HPGDGAA
SCHEMBL4331347 0.83 GAA (0.44) ALDH1A1LMNASMN1; SMN2HPGDGAA
SCHEMBL4330378 0.83 GAA (0.40) ALDH1A1ALOX12SMN1; SMN2GAAMAPT
SCHEMBL4330375 0.83 GAA (0.40) ALDH1A1ALOX12SMN1; SMN2GAAMAPT
SCHEMBL4331965 0.81 SMN1; SMN2 (0.52) ALDH1A1LMNAALOX12SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 ALDH1A1 1459/4885CNR1 1612/4885CNR2 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.